SEC Form SC 13G filed by Disc Medicine Inc.

SEC Form SC 13G filed by Disc Medicine Inc.

Recent Analyst Ratings for $IRON

$IRON Press Releases

$IRON Analyst Ratings

$IRON Insider Trading

$IRON Large Ownership Changes

$IRON Financials

$IRON Leadership Updates

$IRON Insider Purchases

$IRON SEC Filings

Recent Analyst Ratings for
$IRON

$IRON
Press Releases

$IRON
Analyst Ratings

$IRON
Insider Trading

$IRON
Large Ownership Changes

$IRON
Financials

$IRON
Leadership Updates

$IRON
Insider Purchases

$IRON
SEC Filings

Chat with this insight

Fastest customizable press release news feed in the world

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

TD Cowen initiated coverage on Disc Medicine

Disc Medicine upgraded by Morgan Stanley with a new price target

Disc Medicine upgraded by Raymond James with a new price target

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Savage William Jacob sold $105,367 worth of shares (2,100 units at $50.17), decreasing direct ownership by 3% to 66,398 units (SEC Form 4)

Chief Executive Officer Quisel John D exercised 7,000 shares at a strike of $1.01, increasing direct ownership by 5% to 161,828 units (SEC Form 4)

Director Ashiya Mona sold $310,483 worth of shares (5,738 units at $54.11) (SEC Form 4)

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

SEC Form SC 13G filed by Disc Medicine Inc.

Live finance-specific insights

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Live Leadership Updates

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

SEC Form 10-Q filed by Disc Medicine Inc.

Disc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Disc Medicine Inc.

6/25/24 10:06:26 AM ET

$IRON

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IRON alert in real time by email

SC 13G 1 d832951dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. __)*

Disc Medicine, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

254604101

(CUSIP Number)

June 17, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 254604101

(1)

Consists of 1,088,489 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)

Based on (i) 24,721,666 shares of Common Stock outstanding on May 6, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on May 9, 2024, and (ii) 4,944,000 shares of Common Stock that were sold by the Issuer in connection with its public offering as described in the Issuer’s final prospectus filed with the SEC pursuant to Rule 424(b)(5) on June 14, 2024.

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

Consists of 318,843 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

Consists of 67,018 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

Consists of 280,484 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

Consists of (i) 1,088,489 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 318,843 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 67,018 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 280,484 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

Consists of (i) 1,088,489 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 318,843 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

(2)

CUSIP No. 254604101

(1)

(2)

CUSIP No. 254604101

(1)

(2)

Item 1(a).

Name of Issuer: Disc Medicine, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices: 321 Arsenal Street, Suite 101, Watertown, MA 02472

Item 2(a).

Name of Person Filing:

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

Frazier Life Sciences Public Overage Fund, L.P. (“FLSPOF”)

FHMLSP Overage, L.P.

FHMLSP Overage, L.L.C.

Frazier Life Sciences XI, L.P. (“FLS XI”)

FHMLS XI, L.P.

FHMLS XI, L.L.C.

Frazier Life Sciences X, L.P. (“FLS X”)

FHMLS X, L.P.

FHMLS X, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Albert Cha (“Cha”)

James Brush (“Brush”)

Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address and principal business office of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.

1001 Page Mill Rd, Building 4, Suite B

Palo Alto, CA 94304

Item 2(c).

Citizenship:


Entities:	FLSPF	-	Delaware, U.S.A.
	FHMLSP, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLSPOF	-	Delaware, U.S.A.
	FHMLSP Overage, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLS XI	-	Delaware, U.S.A.
	FHMLS XI, L.P.	-	Delaware, U.S.A.
	FHMLS XI, L.L.C.	-	Delaware, U.S.A.
	FLS X	-	Delaware, U.S.A.
	FHMLS X, L.P.	-	Delaware, U.S.A.
	FHMLS X, L.L.C.	-	Delaware, U.S.A.

Individuals:	Topper	-	United States Citizen
	Heron	-	United States Citizen
	Cha	-	United States Citizen
	Brush	-	United States Citizen
	Estes	-	United States Citizen

Item 2(d).

Title of Class of Securities: Common Stock

Item 2(e).

CUSIP Number: 254604101

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


		(a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

		(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);


(c)		☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)		☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K).

		If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: June 25, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.

	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLSP, L.P.

	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.

	By: FHMLSP Overage, L.P., its General Partner
	By: FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLSP OVERAGE, L.P.

	By FHMLSP Overage, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLSP OVERAGE, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FRAZIER LIFE SCIENCES XI, L.P.

	By: FHMLS XI, L.P., its General Partner
	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLS XI, L.P.

	By: FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: June 25, 2024	FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FRAZIER LIFE SCIENCES X, L.P.

	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLS X, L.P.

	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: June 25, 2024	By:	*
		James N. Topper

Date: June 25, 2024	By:	*
		Patrick J. Heron

Date: June 25, 2024	By:	**
		Albert Cha

Date: June 25, 2024	By:	**
		James Brush

Date: June 25, 2024	By:	***
		Daniel Estes

Date: June 25, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Exhibit Index


Exhibit A -		Agreement regarding filing of joint Schedule 13G.

Get the next $IRON alert in real time by email

Date	Price Target	Rating	Analyst
2/27/2025		Buy	TD Cowen
11/5/2024	$85.00	Equal-Weight → Overweight	Morgan Stanley
11/4/2024	$66.00 → $110.00	Outperform → Strong Buy	Raymond James
10/23/2024	$89.00	Buy	Jefferies
10/16/2024		Sector Outperform	Scotiabank
8/22/2024	$75.00	Overweight	Wells Fargo
4/1/2024	$40.00	Strong Buy → Outperform	Raymond James
12/19/2023	$56.00 → $65.00	Overweight → Equal-Weight	Morgan Stanley

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware